BioPorto A/S (BIOPOR.CO)
| Previous close | 3.4300 |
| Open | 3.3150 |
| Bid | 3.3650 x 0 |
| Ask | 3.3850 x 0 |
| Day's range | 3.3150 - 3.4400 |
| 52-week range | 2.6500 - 8.2400 |
| Volume | 104,768 |
| Avg. volume | 534,849 |
| Market cap | 899.653M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings date | 12 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results
August 31, 2021Announcement no. 15 BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results BioPorto A/S (BioPorto) has successfully concluded an interim analysis of data from the pediatric clinical trial being conducting to evaluate The NGAL Test™ as a tool for risk assessment of moderate to severe acute kidney injury (AKI). The study is being conducted to support a regulatory submission to the US Food and Drug Administration (FD
- Globe Newswire
BioPorto Announces Q2 2021 Report
August 18, 2021Announcement no. 14Q2 2021 Report Highlights Solid revenue growth in the first half of 2021 In the first half of 2021, BioPorto’s revenue grew by 20% measured in USD and 11% when measured in DKK, driven by strong sales of antibodies and higher research use only (RUO) sales of The NGAL Test™ in the US. In the second quarter of 2021, revenue from antibodies was up 118% and RUO sales of The NGAL Test in the US increased 84% in USD and 68% in DKK. Enrollment in the US clinical trial o
- Globe Newswire
Pipeline Update Regarding COVID-19 test
June 29, 2021Announcement no. 13 Pipeline Update Regarding COVID-19 test BioPorto A/S (BioPorto) is currently developing a point-of-care test for SARS-CoV-2 on the proprietary gRAD platform designed to quickly and easily identify infected patients using a non-invasive sample. While indicative data from the process and studies in the US and Denmark supports the gRAD platforms strong capabilities as a technology for rapid testing, BioPorto has prioritized to secure a high sensitivity of more than
